Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Phage Display-Based Nanotechnology Applications in Cancer Immunotherapy.

Goracci M, Pignochino Y, Marchiò S.

Molecules. 2020 Feb 14;25(4). pii: E843. doi: 10.3390/molecules25040843. Review.

2.

Delving into PARP inhibition from bench to bedside and back.

Grignani G, Merlini A, Sangiolo D, D'Ambrosio L, Pignochino Y.

Pharmacol Ther. 2020 Feb;206:107446. doi: 10.1016/j.pharmthera.2019.107446. Epub 2019 Nov 19. Review.

PMID:
31756364
3.

ZnO nanocrystals shuttled by extracellular vesicles as effective Trojan nano-horses against cancer cells.

Dumontel B, Susa F, Limongi T, Canta M, Racca L, Chiodoni A, Garino N, Chiabotto G, Centomo ML, Pignochino Y, Cauda V.

Nanomedicine (Lond). 2019 Nov;14(21):2815-2833. doi: 10.2217/nnm-2019-0231. Epub 2019 Nov 21.

4.

Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation.

De Feo A, Sciandra M, Ferracin M, Felicetti F, Astolfi A, Pignochino Y, Picci P, Carè A, Scotlandi K.

Cell Death Dis. 2019 Jun 17;10(7):471. doi: 10.1038/s41419-019-1675-1.

5.

Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.

Cova E, Pandolfi L, Colombo M, Frangipane V, Inghilleri S, Morosini M, Mrakic-Sposta S, Moretti S, Monti M, Pignochino Y, Benvenuti S, Prosperi D, Stella G, Morbini P, Meloni F.

Int J Nanomedicine. 2019 Jan 23;14:773-785. doi: 10.2147/IJN.S186344. eCollection 2019.

6.

Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.

Mesiano G, Grignani G, Fiorino E, Leuci V, Rotolo R, D'Ambrosio L, Salfi C, Gammaitoni L, Giraudo L, Pisacane A, Butera S, Pignochino Y, Basiricó M, Capozzi F, Sapino A, Aglietta M, Sangiolo D.

Oncoimmunology. 2018 Aug 6;7(11):e1465161. doi: 10.1080/2162402X.2018.1465161. eCollection 2018.

7.

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.

Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M.

Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11.

PMID:
30217671
8.

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.

Pignochino Y, Capozzi F, D'Ambrosio L, Dell'Aglio C, Basiricò M, Canta M, Lorenzato A, Vignolo Lutati F, Aliberti S, Palesandro E, Boccone P, Galizia D, Miano S, Chiabotto G, Napione L, Gammaitoni L, Sangiolo D, Benassi MS, Pasini B, Chiorino G, Aglietta M, Grignani G.

Mol Cancer. 2017 Apr 28;16(1):86. doi: 10.1186/s12943-017-0652-5.

9.

Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.

D'Ambrosio L, Palesandro E, Boccone P, Tolomeo F, Miano S, Galizia D, Manca A, Chiara G, Bertotto I, Russo F, Campanella D, Venesio T, Sangiolo D, Pignochino Y, Siatis D, De Simone M, Ferrero A, Pisacane A, Dei Tos AP, Aliberti S, Aglietta M, Grignani G.

Eur J Cancer. 2017 Jun;78:122-132. doi: 10.1016/j.ejca.2017.03.025. Epub 2017 Apr 24.

PMID:
28448856
10.

Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.

Gammaitoni L, Giraudo L, Macagno M, Leuci V, Mesiano G, Rotolo R, Sassi F, Sanlorenzo M, Zaccagna A, Pisacane A, Senetta R, Cangemi M, Cattaneo G, Martin V, Coha V, Gallo S, Pignochino Y, Sapino A, Grignani G, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2017 May 1;23(9):2277-2288. doi: 10.1158/1078-0432.CCR-16-1524. Epub 2016 Nov 4.

11.

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.

Pignochino Y, Dell'Aglio C, Inghilleri S, Zorzetto M, Basiricò M, Capozzi F, Canta M, Piloni D, Cemmi F, Sangiolo D, Gammaitoni L, Soster M, Marchiò S, Pozzi E, Morbini P, Luisetti M, Aglietta M, Grignani G, Stella GM.

BMC Cancer. 2015 May 8;15:374. doi: 10.1186/s12885-015-1363-1.

12.

Adoptive immunotherapy against sarcomas.

Mesiano G, Leuci V, Giraudo L, Gammaitoni L, Carnevale Schianca F, Cangemi M, Rotolo R, Capellero S, Pignochino Y, Grignani G, Aglietta M, Sangiolo D.

Expert Opin Biol Ther. 2015 Apr;15(4):517-28. doi: 10.1517/14712598.2015.987121. Epub 2014 Dec 16. Review.

PMID:
25516119
13.

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.

Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, Capozzi F, Biagini R, Gambarotti M, Fagioli F, Casali PG, Picci P, Ferrari S, Aglietta M; Italian Sarcoma Group.

Lancet Oncol. 2015 Jan;16(1):98-107. doi: 10.1016/S1470-2045(14)71136-2. Epub 2014 Dec 11.

14.

Activation of oncogenic pathways in idiopathic pulmonary fibrosis.

Stella GM, Inghilleri S, Pignochino Y, Zorzetto M, Oggionni T, Morbini P, Luisetti M.

Transl Oncol. 2014 Oct;7(5):650-5. doi: 10.1016/j.tranon.2014.05.002. Epub 2014 Jun 14.

15.

Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.

Sangiolo D, Mesiano G, Gammaitoni L, Leuci V, Todorovic M, Giraudo L, Cammarata C, Dell'Aglio C, D'Ambrosio L, Pisacane A, Sarotto I, Miano S, Ferrero I, Carnevale-Schianca F, Pignochino Y, Sassi F, Bertotti A, Piacibello W, Fagioli F, Aglietta M, Grignani G.

Cancer Res. 2014 Jan 1;74(1):119-29. doi: 10.1158/0008-5472.CAN-13-1559. Epub 2013 Dec 19.

16.
17.

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features.

Gammaitoni L, Giraudo L, Leuci V, Todorovic M, Mesiano G, Picciotto F, Pisacane A, Zaccagna A, Volpe MG, Gallo S, Caravelli D, Giacone E, Venesio T, Balsamo A, Pignochino Y, Grignani G, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2013 Aug 15;19(16):4347-58. doi: 10.1158/1078-0432.CCR-13-0061. Epub 2013 Jun 21.

18.

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.

Pignochino Y, Dell'Aglio C, Basiricò M, Capozzi F, Soster M, Marchiò S, Bruno S, Gammaitoni L, Sangiolo D, Torchiaro E, D'Ambrosio L, Fagioli F, Ferrari S, Alberghini M, Picci P, Aglietta M, Grignani G.

Clin Cancer Res. 2013 Apr 15;19(8):2117-31. doi: 10.1158/1078-0432.CCR-12-2293. Epub 2013 Feb 22.

19.

Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers.

Todorovic M, Mesiano G, Gammaitoni L, Leuci V, Giraudo Diego L, Cammarata C, Jordaney N, Carnevale-Schianca F, Gallo S, Fagioli F, Piacibello W, Elia AR, Pignochino Y, Dell'aglio C, Grignani G, Cignetti A, Aglietta M, Sangiolo D.

J Immunother. 2012 Sep;35(7):579-86.

PMID:
22892454
20.

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.

Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, Pignochino Y, Cavalloni G, Torchio B, Mosso L, Chiorino G, Aglietta M.

BMC Cancer. 2011 Jan 25;11:31. doi: 10.1186/1471-2407-11-31.

Supplemental Content

Loading ...
Support Center